All In Biotech

Drug Trial Radar · NCT02187159

Treatment of Pain Associated With Fibromyalgia

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,270 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,270

Actual

Start

Nov 2014

Primary completion

Jul 7, 2016

Study completion Jul 7, 2016

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Jul 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.

Conditions

  • Pain Associated With Fibromyalgia

Interventions

  • DS-5565Drug

    DS-5565 15 mg tablet for oral administration

  • PregabalinDrug

    Pregabalin 150 mg capsule for oral administration

  • Placebo tabletDrug

    Placebo tablet (matching DS5565) for oral administration

  • Placebo capsuleDrug

    Placebo capsule (matching pregabalin) for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or PlaceboTime frame: Baseline up to Week 13 postdose

Locations

176 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fresno, California

  • Site not named

    Glendale, California

  • Site not named

    Orange, California

  • Site not named

    Oxnard, California

  • Site not named

    Richmond, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Ana, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Simi Valley, California

  • Site not named

    New London, Connecticut

  • Site not named

    Bradenton, Florida

  • Site not named

    Brandon, Florida

  • Site not named

    DeBary, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Homestead, Florida

  • Site not named

    Lake Mary, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Plant City, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Meridian, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Gurnee, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Shawnee Mission, Kansas

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.